Version françaiseEnglish version
RD Biotech / Molecular biology / Biologie MoléculaireRD Biotech / Services analytiques / Analytical servicesRD Biotech / Anticorps monoclonaux (mAb) / Monoclonal antibodiesRD Biotech / ELISARD Biotech / Culture Cellulaire / Cell cultureRD Biotech / Production de cellules / Cell production



3 rue Henri Baigue

F-25000 Besançon

+33(0)3 81 53 88 37

Biotech Investissement

RD-BIOTECH is now a sister company of DIACLONE and SYNABS, for a better synergy in the field of monoclonal antibodies!

Read more

Careers with RD Biotech

Please apply using the online application form


News from RD-Biotech

NEW! RD-Biotech supplier of murine monoclonal antibody D1-25, for the quantification of rabies virus by ELISA.

Signature of a license agreement with Institut Pasteur - France: RD-Biotech becomes the supplier of the clone D1-25 (anti-rabies virus monoclonal antibody).

  • Clone: D1-25
  • Isotype: mouse IgG1
  • Target species: Human
  • Specificity: Glycoprotein G of rabies virus
  • Application: ELISA and other (contact us)
  • Format: Biotinylated (Code RDB-D1.25b) or Purified (Code RDB-D1.25p)
  • Quantity: 100 μg and 200 μg
  • Form: Freeze-dried
A team of experts at your disposal, contact us for more information:

Innovation and New Trends in Biopharma Outsourcing - Paris - June 18 and 19th, 2019

RD-Biotech and mAbexperts Group will be present at the thematic days « Innovation and New Trends in Biopharma Outsourcing » organized by Buzz4Bio-Connection – Paris Dauphine – June 18 and 19th, 2019.
Come and meet us on our booth! We will be happy to present our services & products, especially our Biomanufacturing services (Plasmids, Monoclonal antibodies, Recombinant proteins) and our new custom services in Antibody Engineering: mAb sequencing, Development and Production of recombinant antibodies, Humanization Services and Phage Display.
We look forward to seeing you in Paris!

Do not hesitate to contact us at

Immunotherapy - Pornic (France) - June, 13 & 14th, 2019

Diaclone, RD-Biotech and mAbexperts Group will be present at the annual scientific meetings « Immunotherapy », , organized by the Cancéropole Grand Ouest – Pornic (France) - June, 13 & 14th, 2019.
RD-Biotech will give a speech on Friday, June 14 at 11:15 about “new services in Biomanufacturing and Antibody Engineering: Antibody Sequencing, Development and Production of Recombinant Antibodies, Humanization Services and Phage Display, Production and Purification of Antibodies monoclonal and recombinant.
Nous serons heureux de vous rencontrer sur notre stand lors de ces journées. We will be happy to meet you at our booth during these days.

Do not hesitate to contact us at

Discover and test our fastELISA Kits: The quickest ELISA Kits on the market!

Easy one-step process – Results in less than 30 minutes – Coloured pipetting tracking – Ready-to-use reagents

  • Immunoglobulin quantification (Screening of therapeutic antibodies, Production monitoring, Selection of ‘good producer’ clones, Pharmacokinetics, Validation of vectors, ...)
  • Immunoglobulin isotyping
  • Cell contaminant detection
  • And new kits coming soon!

Contact us to find out more at

New: Recombinant antibody platform! A expert team at your service for a complete service!

From the generation of hybridomas, to the production and purification of monoclonal antibodies from a few mg to several grams.
Sequencing of your monoclonal antibodies, chimerization, humanization and production.
Phage display technology.
Characterization and validation of specificity: affinity, bioactivity ... (ELISA, Octet, Cytometry, bioassays...)
Contact us!

QVQ joins the Biotech Investissement Group

We are pleased to announce that QVQ, a company based in Utrecht (The Netherlands), is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (Biotech Investissement Group –

QVQ has strong expertise in the development and production of single domain antibodies derived from llamas, which are referred to as VHHs. VHHs have unique biochemical properties due to their small size and high stability which make them very useful for tumor targeting particularly in imaging technologies and companion diagnostics. QVQ offers multiple services related to development, reformatting and optimization of VHHs with respect to stability, production levels and humanization. Besides contract research and services, QVQ has developed a growing portfolio of proprietary detection/imaging VHHs directed against targets in disease related with oncology, age disease and infectious diseases.
By joining the Biotech Investissement group, QVQ will complement the high level of expertise already present within the group, to develop and market new high-quality diagnostic assays and imaging products.

Please do not hesitate to get in touch if you require information about the QVQ products and services.

PSL Alliance

RD-Biotech is a core member of the PSL Alliance, a network of biotech companies gathered by UK-based company Pivotal Scientific Limited.